Mitchell Jimmy T, Johnson Eric B
Department of Clinical Sciences, Alabama College of Osteopathic Medicine, Dothan, USA.
Department of Anatomy and Molecular Medicine, Alabama College of Osteopathic Medicine, Dothan, USA.
Cureus. 2023 Jan 10;15(1):e33592. doi: 10.7759/cureus.33592. eCollection 2023 Jan.
Introduction Human pathogenic coding variations of the galactose-1-phosphate uridylyltransferase (GALT) gene cause classic galactosemia, a recessive disease of galactose metabolism. Unfortunately, there are many variants of uncertain significance (VUS) that need to be characterized in order to be able to predict the likelihood of classic galactosemia for all possible genotypes. There are many bioinformatic resources available that attempt to predict the pathogenicity of a human variant, but it is unclear if these methods realistically predict the consequence of these variants. To determine the clinical application of these resources, we compared the results of enzymatic assays with predictive models. Methods In all assays, we compared the activity of the three human GALT VUS (Alanine81Threonine, Histidine47Aspartate, Glutamate58Lysine) to native GALT (nGALT) and to a variant of known pathogenic clinical significance (Glutamine188Arginine). The enzymatic activities of VUS recombinant proteins were compared to the results of analytical methods. The methods included the comparison of molecular dynamic simulation root-mean-square deviation (RMSD) results and the results from predictive programs PredictSNP, evolutionary model of variant effect (EVE), ConSurf, and sorting intolerant from tolerant (SIFT). Results The enzymatic assays showed that the variants tested had diminished Vmax relative to the native protein. The VUS RMSD data for both the whole protein and individual residues in the molecular dynamics simulations were not significantly different when compared to nGALT. The other predictive programs had mixed results for each VUS and were not consistent with the enzyme activity or simulation results. Conclusions Our experiments indicated a statistically significant decrease in enzymatic activity of the VUS when compared to nGALT. These experiments also demonstrated significant differences between predictions and results. These results suggest that the in silico tools used may not be beneficial in determining the pathogenicity of GALT VUS.
引言 半乳糖-1-磷酸尿苷酰转移酶(GALT)基因的人类致病编码变异会导致经典型半乳糖血症,这是一种半乳糖代谢的隐性疾病。不幸的是,有许多意义未明的变异(VUS)需要进行特征描述,以便能够预测所有可能基因型患经典型半乳糖血症的可能性。有许多生物信息学资源试图预测人类变异的致病性,但尚不清楚这些方法是否能真实地预测这些变异的后果。为了确定这些资源的临床应用,我们将酶活性测定结果与预测模型进行了比较。
方法 在所有测定中,我们将三种人类GALT VUS(丙氨酸81苏氨酸、组氨酸47天冬氨酸、谷氨酸58赖氨酸)的活性与天然GALT(nGALT)以及具有已知致病临床意义的变异(谷氨酰胺188精氨酸)进行了比较。将VUS重组蛋白的酶活性与分析方法的结果进行了比较。这些方法包括分子动力学模拟均方根偏差(RMSD)结果的比较以及预测程序PredictSNP、变异效应进化模型(EVE)、ConSurf和容忍与不容忍排序(SIFT)的结果。
结果 酶活性测定表明,所测试的变异相对于天然蛋白的Vmax有所降低。分子动力学模拟中整个蛋白和单个残基的VUS RMSD数据与nGALT相比无显著差异。其他预测程序对每个VUS的结果参差不齐,且与酶活性或模拟结果不一致。
结论 我们的实验表明,与nGALT相比,VUS的酶活性有统计学意义的降低。这些实验还证明了预测结果与实际结果之间存在显著差异。这些结果表明,所使用的计算机模拟工具可能无助于确定GALT VUS的致病性。